GLG News Analyses of the following article:

Onglyza receives positive opinion in Europe for type 2 diabetes

Published at: www.pharmabiz.com

July 1, 2009

Saxagliptin, perhaps the DPP-IV inhibitor with the best name is on the verge of being granted a license in Europe. This will be the third DPP-IV inhibitor available for use in Europe, and is likely to have the same blip in use followed by a prolonged lull whilst the wait for long-term safety data takes place. Like all new drugs for type 2 diabetes mellitus, it has the magic 1% HbA1c reduction, and...

Request a News Analysis

Subscribe to Updates

By RSS

Work for one of the world's leading organizations? Get started now.

Get Intelligently Connected
with the world's leading experts

GLG's 850+ Clients Include:

More than 70% of the world's leading: mutual funds
15 of the leading 20: global banks
7 of the leading 10: global private equity firms
5 of the leading 10: AmLaw firms
Fortune 500^® Companies: in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software

Onglyza receives positive opinion in Europe for type 2 diabetes

Work for one of the world's leading organizations? Get started now.

Get Intelligently Connectedwith the world's leading experts

GLG's 850+ Clients Include:

Get Intelligently Connected
with the world's leading experts